The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available only under special arrangements under the Section ...
Daratumumab gets PBS listing recommendation after ‘disgraceful’ delay
By Mardi Chapman
3 Sep 2020